Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation by beta-amyloid in Alzheimer disease.

J Rogers1, N R Cooper, S Webster

  • 1L. J. Roberts Center, Sun Health Research Institute, Sun City, AZ 85351.

Proceedings of the National Academy of Sciences of the United States of America
|November 1, 1992
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement activation by neurofibrillary tangles in Alzheimer's disease.

Neuroscience letters·2001
Same author

Inflammation and Alzheimer's disease.

Neurobiology of aging·2000
Same author

Pelvic bioelectrical impedance measurements to detect rectal filling.

Physiological measurement·1998
Same author

Teratoma with trisomy 16 in a baboon (Papio hamadryas).

American journal of primatology·1998
Same author

Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip.

Chest·1998
Same author

Obesity in older persons.

Journal of the American Dietetic Association·1998

This study explores how beta-amyloid, a protein linked to Alzheimer's disease, might trigger immune responses in the brain. The researchers found evidence that beta-amyloid can activate a part of the immune system called the classical complement pathway, even without antibodies. They tested this in lab experiments and also observed it in brain tissue from people with Alzheimer's. These findings suggest that immune responses may play a role in the progression of Alzheimer's disease. The study does not claim this is the only cause of the disease, but it adds to the understanding of how the immune system might interact with amyloid pathology.

Area of Science:

  • Neuroimmunology
  • Alzheimer's disease pathogenesis
  • Complement system in neurodegeneration

Background:

Alzheimer disease (AD) involves accumulation of beta-amyloid peptides in the brain. Researchers have long observed that these peptides may contribute to neurotoxicity. However, the exact mechanism by which beta-amyloid causes damage remains unresolved. Prior studies have focused on amyloid aggregation and its effects on neurons. No prior work had resolved how beta-amyloid might interact with immune pathways. This gap motivated investigations into the role of the complement system. The complement system is known to respond to pathogens and cellular debris. Its involvement in AD pathology had not been fully characterized. This paper addresses the need to explore immune responses in AD brains.

Purpose Of The Study:

The aim of this study was to investigate whether beta-amyloid can activate the complement system. The researchers sought to determine if this activation occurs in AD brains. They focused on the classical complement pathway, which typically requires antibodies. The study tested if beta-amyloid could trigger this pathway independently of antibodies. The motivation was to uncover a potential mechanism for neurotoxicity in AD. The researchers proposed that complement activation might contribute to brain damage. This work aimed to provide both in vitro and in situ evidence for this hypothesis. The findings could clarify how immune responses interact with amyloid pathology.

Keywords:
beta-amyloidcomplement systemAlzheimer's diseaseneuroimmunology

Frequently Asked Questions

The authors propose that beta-amyloid binds and activates the classical complement pathway in the absence of antibody. This activation occurs in vitro and is observed in situ in AD brain regions.

The study used in vitro biochemical assays and immunohistochemistry on AD brain tissue to detect complement components associated with amyloid pathology.

The classical pathway typically requires antibodies, but this study shows it can be activated by beta-amyloid alone. This suggests a novel mechanism for immune involvement in AD.

Immunohistochemistry detected complement components in areas of AD pathology, such as amyloid plaques. This in situ evidence supports the role of complement in AD brains.

Related Experiment Videos

Main Methods:

The researchers used in vitro experiments to test beta-amyloid's ability to bind and activate the classical complement pathway. They assessed complement activation in the absence of antibodies. They employed biochemical assays to detect complement components. The study also included in situ analysis of AD brain tissue. Immunohistochemistry was used to identify complement markers in pathological regions. The methods focused on detecting complement activation in areas with amyloid deposits. The team compared findings from AD brains to control samples. The experimental design aimed to confirm complement involvement in AD pathology.

Main Results:

The study found that beta-amyloid can bind and activate the classical complement pathway in vitro. This activation occurred without the presence of antibodies. Complement components were detected in association with amyloid plaques in AD brains. The findings suggest a direct interaction between beta-amyloid and complement proteins. The in situ evidence showed complement activation in regions of AD pathology. The results support a role for the complement system in AD progression. The data indicate that beta-amyloid may trigger immune responses in the brain. These findings provide a novel perspective on AD pathogenesis.

Conclusions:

The authors propose that beta-amyloid activates the classical complement pathway in AD brains. This activation may occur independently of antibody involvement. The findings suggest a potential mechanism for neurotoxicity in AD. The complement system's role in AD pathology is highlighted in this work. The study supports the idea that immune responses contribute to AD progression. The evidence is limited to in vitro and in situ observations. The authors do not claim that complement activation is essential for AD pathology. These conclusions are based on the specific findings presented in the paper.

The authors do not propose new therapeutic targets. They focus on mechanisms and do not suggest interventions based on these findings.

The findings suggest that immune responses, specifically complement activation, may contribute to AD progression. This adds a new layer to the understanding of AD pathology.